MSD Innovation Factory is looking for digital solutions for anaesthesiologists

MSD is looking for innovators to solve 7 health-related challenges. One of them seeks to support anaesthesiologists with their continuous education (e.g. at the operation room) or their team building with surgeons. As a leading pharmaceutical company, MSD is aware of the need to incorporate innovation to deliver the best possible value to healthcare professionals, patients and customers. And that is the MSD Innovation Factory, where three out of the seven finalists (one per challenge) will get the top prize: up to $20,000 each to develop and locally launch the solution.

Co-create with a pharma and go together for unmet needs

MSD is having difficulty to reach anaesthesiologists to share the benefits of using Deep Block (DB) until the end of operations. Deep Block improves surgical conditions as it decreases the movement of the muscles and increases the volume at the operation area.

The main reason for not reaching them is their busy workload and the time spent at operation rooms, where MSD representatives cannot enter. There’s an opportunity for solutions oriented to education, e.g. while at the operating room, communication and team building with surgeons.

Worldwide participants are welcome to apply proposing solutions that will be implemented first in Turkey. The finalist of this challenge will have the opportunity to improve the proposal in collaboration with the local MSD team that proposed the challenge.

Find all the info about the anaesthesiologists challenge: https://www.msdinnovationfactory.com/challenges/anestouch/

Do you have a solution? Apply now!
www.msdinnovationfactory.com

How MSD Innovation Factory works

The innovation factory initiative aims to give support to the companies that come up with the best ideas to solve one of the 7 challenges identified in the EEMEA Region (Eastern Europe, Middle East and Africa) by local MSD teams.

The selection is done in four steps:

  • Solutions submitted before 31st October are reviewed by the challenge owners (the local MSD teams).
  • Each country will select the best solution for its proposed challenge.
  • During co-creation sessions the selected company and the local MSD team will work together in an improved proposal to be jointly presented in a Final event.
  • At the Final event in January 2018, the 7 finalists will pitch their solution in front of a senior jury from MSD. The jury will award 3 winners.

The prizes

Each of the 3 winners will receive the following:
  • Up to $20,000 to pilot their solution in the challenge-related local market.
  • Support from MSD local team to connect with the local ecosystem (eg. medical professional associations), deal with potential regulatory issues and disseminate leveraging MSD local channels. It will also contribute with expertise and business know-how.
  • If the local launch is a success after 12 months, its outcomes will be globally shared within MSD to investigate further implementation beyond the initial market.

All 7 finalists will get a 500€ grant to cover travel expenses to attend the Final event in Istanbul, and the opportunity to optimize their proposal in collaboration with the local MSD team that proposed the challenge. They will also receive visibility through the initiative communication channels.

MSD is a global healthcare company with a 125-year history committed to being the premier, research-intensive biopharmaceutical company and are dedicated to providing leading innovations and solutions for today and the future.

Applications until 31 October

Do you have a solution? Apply now!
www.msdinnovationfactory.com

Most Popular Now

Sustained cellular immune dysregulation in individ…

COVID-19, which has killed 1.7 million people worldwide, does not follow a uniform path. Many infected patients remain asymptomatic or have mild symptoms. Others, espe...

New virtual screening strategy identifies existing…

A novel computational drug screening strategy combined with lab experiments suggest that pralatrexate, a chemotherapy medication originally developed to treat lymphoma, c...

An in vitro study shows Pfizer-BioNTech COVID-19 v…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from an in vitro study conducted by Pfizer and the University of Texas Medical Branch (UTMB...

European Commission authorizes COVID-19 vaccine Mo…

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the European Commission has granted a cond...

Serum Institute of India obtains emergency use aut…

AstraZeneca's COVID-19 vaccine has been granted emergency use authorisation in India as well as Argentina, Dominican Republic, El Salvador, Mexico and Morocco for the act...

CureVac and Bayer join forces on COVID-19 vaccine …

Bayer has signed a collaboration and services agreement with CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines b...

New findings help explain how COVID-19 overpowers …

Seeking to understand why COVID-19 is able to suppress the body's immune response, new research from the USC Leonard Davis School of Gerontology suggests that mitochondri...

Valneva in advanced discussions with European Comm…

Valneva SE, a specialty vaccine company focused on prevention of infectious diseases with significant unmet medical need, announced it is in advanced discussions with the...

China grants conditional market approval for Sinop…

The inactivated COVID-19 vaccine developed by Beijing Institute of Biological Products of Sinopharm CNBG has been granted conditional registration by the NMPA of China, C...

Novavax announces initiation of PREVENT-19 pivotal…

Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced initiation of PREVEN...

Scientists identify 'immune cop' that detects SARS…

Scientists at Sanford Burnham Prebys Medical Discovery Institute have identified the sensor in human lungs that detects SARS-CoV-2 and signals that it's time to mount an ...

AstraZeneca's COVID-19 vaccine authorised for emer…

AstraZeneca's COVID-19 vaccine has been approved for emergency supply in the UK, with the first doses being released today so that vaccinations may begin early in the New...